This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
352
Administered SC
Administered SC
Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)
Time frame: Week 16
Mean Change from Baseline in Total Number of Abscesses and Inflammatory Nodules
Time frame: Baseline, Week 16
Mean Change from Baseline in HS-related Average Skin Pain Numerical Rating Scale (NRS)
Time frame: Baseline, Week 16
Pharmacokinetics (PK): Plasma Concentrations of Eltrekibart
Time frame: Baseline through Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medical Dermatology Specialists
Phoenix, Arizona, United States
Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix, Arizona, United States
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Dermatology Institute and Skin Care Center
Santa Monica, California, United States
University of Connecticut
Farmington, Connecticut, United States
Direct Helpers Research Center
Hialeah, Florida, United States
...and 64 more locations